---
title: AHCC Publications
permalink: /ahcc/publications/
description: ""
variant: tiptap
---
<h1><strong>AHCC Publications</strong></h1>
<ol data-tight="true" class="tight">
<li>
<p>Chan SL, Sun H, Xu Y, Zeng H, … Chew V, <strong>Chow PKH</strong>, Yau
T, Kudo M, Fan J, Zhou J. The Lancet Commission on addressing the global
hepatocellular carcinoma burden: comprehensive strategies from prevention
to treatment. Lancet. 2025 Aug 16;406(10504):731-778. doi: 10.1016/S0140-6736(25)01042-6.</p>
</li>
<li>
<p>Chen JB, Kaya NA, Zhang Y, …, <strong>Chow PKH</strong> et. al. A multimodal
atlas of hepatocellular carcinoma reveals convergent evolutionary paths
and 'bad apple' effect on clinical trajectory. J Hep. May 2024; <a href="https://doi.org/10.1016/j.jhep.2024.05.017" rel="noopener noreferrer nofollow" target="_blank">https://doi.org/10.1016/j.jhep.2024.05.017</a>
</p>
</li>
<li>
<p>Li Z, Pai R, Gupta S, … <strong>Chow PKH </strong>et al. Presence of onco-fetal
neighborhoods in hepatocellular carcinoma is associated with relapse and
response to immunotherapy. Nat Cancer. Jan 2024;5(1):167-186. doi:10.1038/s43018-023-00672-2</p>
</li>
<li>
<p>Xu J, Zheng M, Thng DKH, <strong>Chow PKH</strong> et al. <a href="http://NanoBeacon.AI" rel="noopener noreferrer nofollow" target="_blank">NanoBeacon.AI</a>:
AI-Enhanced Nanodiamond Biosensor for Automated Sensitivity Prediction
to Oxidative Phosphorylation Inhibitors. ACS Sens. May 26 2023;8(5):1989-1999.
doi:10.1021/acssensors.3c00126</p>
</li>
<li>
<p>Sim YK, Chong MC, Gandhi M, Pokharkar YM, Zhu Y, Shi L, Lequn L, Chen
CH, Kudo M, Lee JH, Strasser SI, Chanwat R, <strong>Chow PKH</strong>; Asia-Pacific
Hepatocellular Carcinoma Trials Group. Real-World Data on the Diagnosis,
Treatment, and Management of Hepatocellular Carcinoma in the Asia-Pacific:
The INSIGHT Study. Liver Cancer. 2023 Oct 9;13(3):298-313. doi: 10.1159/000534513</p>
</li>
<li>
<p>Thng DKH, Hooi L, Toh CCM, Lim JJ, Rajagopalan D, Syariff IQC, Tan ZM,
Rashid MBMA, Zhou L, Kow AWC, Bonney GK, Goh BKP, Kam JH, Jha S, Dan YY,&nbsp;<strong>Chow PKH,</strong>&nbsp;Toh
TB, Chow EK (2023). Histone-lysine N-methyltransferase EHMT2 (G9a) inhibition
mitigates tumorigenicity in Myc-driven liver cancer. Mol Oncol, https://doi.org/10.1002/1878-0261.13417</p>
</li>
<li>
<p>Jeon AJ, Teo YY, Sekar K, Chong SL, Wu L, Chew SC, Chen J, Kendarsari
RI, Lai H, Ling WH, Kaya NA, Lim JQ, Ramasamy A, Oguz G, …, Goh BKP, Tucker-Kellogg
G, Foo RSY,&nbsp;<strong>Chow PKH</strong>. (2023) Multi-region sampling
with paired sample sequencing analyses reveals sub-groups of patients with
novel patient-specific dysregulation in Hepatocellular Carcinoma. BMC Cancer,
23(1):118. https://doi.org/10.1186/s12885-022-10444-3</p>
</li>
<li>
<p>Thng DKH, Toh TB, Pigini P, Hooi L, Dan YY,&nbsp;<strong>Chow PK</strong>,
Bonney GK, Rashid MBMA, Guccione E, Wee DKB, Chow EK. (2022) Splice-switch
oligonucleotide-based combinatorial platform prioritizes synthetic lethal
targets CHK1 and BRD4 against MYC-driven hepatocellular carcinoma. Bioeng
Transl Med, 8(1):e10363. https://doi.org/10.1002/btm2.10363</p>
</li>
<li>
<p>Lee YH, Chuah S, Nguyen PHD, Lim CJ, Lai HLH, Wasser M, …,&nbsp;<strong>Chow PKH</strong>,
Albani S, Liu H, Chew V (2022) IFNγ-IL-17+ CD8 T cells contribute to immunosuppression
and tumor progression in human hepatocellular carcinoma, Cancer Lett, 552:215977.
https://doi.org/10.1016/j.canlet.2022.215977</p>
</li>
<li>
<p>Chan JJ, Zhang B, Chew XH, Salhi A, Kwok ZH, Lim CY, …, Chen L, Gao X,&nbsp;<strong>Chow PKH</strong>,
Yang H, Tay Y. (2022) Pan-cancer pervasive upregulation of 3' UTR splicing
drives tumourigenesis. Nat. Cell Biol., https://doi.org/10.1038/s41556-022-00913-z</p>
</li>
<li>
<p>Lim JTC, Kwang LG, Ho NCW, Toh CCM, Too DSH, Hooi L, Benoukraf T, Chow
PKH, Dan YY, Chow EKH, Toh TB, Fong ELS. (2022) Hepatocellular carcinoma
organoid co-cultures mimic angiocrine crosstalk to generate inflammatory
tumor microenvironment. Biomaterials, 284:121527. https://doi.org/10.1016/j.biomaterials.2022.121527</p>
</li>
<li>
<p>Nguyen PHD, Wasser M, Tan CT, Lim CJ, Lai HLH, Seow JJW, DasGupta R, Phua
CZJ, Ma S, … Zhai WW, Albani S,&nbsp;<strong>Chow PKH</strong>, Chew V.
(2022) Trajectory of immune evasion and cancer progression in hepatocellular
carcinoma.&nbsp;<em>Nat Commun</em>., 13(1):1441. https://doi.org/ 0.1038/s41467-022-29122-w</p>
</li>
<li>
<p>Zhai WW, Lai H, Kaya NA, Chen J, Yang HC, Lu BX, …, Tam WL, Toh HC, Foo
RSY,&nbsp;<strong>Chow PKH</strong>. Dynamic phenotypic heterogeneity and
the evolution of multiple RNA subtypes in Hepatocellular Carcinoma: the
PLANET study, Nat. Sci. Rev. https://doi.org/10.1093/nsr/nwab192</p>
</li>
<li>
<p>Ogasawara S, Choo SP, Li JT, Yoo C, Wang B, Lee D,&nbsp;<strong>Chow PKH</strong>.
(2021) Evolving Treatment of Advanced Hepatocellular Carcinoma in the Asia–Pacific
Region: A Review and Multidisciplinary Expert Opinion. Cancers, 13:2626.
https://doi.org/10.3390/ cancers13112626</p>
</li>
<li>
<p>Nguyen PHD, Ma S, Phua CZJ, Kaya NA, Lai HLH, Lim CJ, Lim JQ, Wasser M,
Lai L, Tam WL, Lim TKH, Wan WK, Loh T, Leow WQ, Pang YH, Chan CY, Lee SY,
Cheow PC, Toh HC, Ginhoux F, Iyer S, Kow AWC, Young Dan Y, Chung A, Goh
BKP, Albani S,&nbsp;<strong>Chow PKH</strong>, Zhai W, Chew V. (2021) Author
Correction: Intratumoural immune heterogeneity as a hallmark of tumour
evolution and progression in hepatocellular carcinoma. Nat Commun., 12(1):1372.
https://doi.org/10.1038/s41467-021-21556-y</p>
</li>
<li>
<p>Suthen S, Lim CJ, Nguyen PHD, Dutertre CA, Lai HLH, Wasser M, Chua C,
…, Zhai WW, Ginhoux F,&nbsp;<strong>Chow PKH</strong>, Albani S, Chew V.
(2022) Hypoxia-driven immunosuppression by Treg and type-2 conventional
dendritic cells in HCC. Hepatology, https://doi.org/ 10.1002/hep.32419</p>
</li>
<li>
<p>Tan SLW, Israeli E, Ericksen RE,&nbsp;<strong>Chow PKH</strong>, Han W.
(2022) The altered lipidome of hepatocellular carcinoma. Semin Cancer Biol.,
S1044-579X(22)00025-6. https://doi.org/ 10.1016/j.semcancer.2022.02.004</p>
</li>
<li>
<p>Zhai WW, Lai H, Kaya NA, Chen J, Yang HC, Lu BX, …, Tam WL, Toh HC, Foo
RSY,&nbsp;<strong>Chow PKH</strong>. Dynamic phenotypic heterogeneity and
the evolution of multiple RNA subtypes in Hepatocellular Carcinoma: the
PLANET study, Nat. Sci. Rev. https://doi.org/10.1093/nsr/nwab192</p>
</li>
<li>
<p>Chew SC, Choo SY,&nbsp;<strong>Chow PKH</strong>. (2021) A new perspective
on the immune escape mechanism in HCC: onco-foetal reprogramming. Br. J.
Cancer. https://doi.org/10.1038/s41416-021-01286-0.</p>
</li>
<li>
<p>Chew XH, Sultana R, Mathew EN, Ng DCE, Lo RHG, Toh HC, Tai D, Choo SP,
Goh BKP, Yan SX, Loke KSH, Thang SP, Gogna A, Venkatanarasimha NK, Tong
AKT, Moe FNN, Chua JSS, Ang RWT, Ong AD, Ng AWY, Hoang MTQ, Too CW, Thng
CH, Chan WY, Kee W, Chan JHM, Irani F, Leong S, Lim KH, Wang MLC, Chow
PKH. (2021) Real-World Data on Clinical Outcomes of Patients with Liver
Cancer: A Prospective Validation of the National Cancer Centre Singapore
Consensus Guidelines for the Management of Hepatocellular Carcinoma. Liver
Cancer. https://doi.org/10.1159/000514400</p>
</li>
<li>
<p>Nguyen PHD, Ma S, Phua CZJ, Kaya NA, Lai HLH, Lim CJ, Lim JQ, Wasser M,
Lai L, Tam WL, Lim TKH, Wan WK, Loh T, Leow WQ, Pang YH, Chan CY, Lee SY,
Cheow PC, Toh HC, Ginhoux F, Iyer S, Kow AWC, Young Dan Y, Chung A, Goh
BKP, Albani S,&nbsp;<strong>Chow PKH</strong>, Zhai W, Chew V. (2021) Intratumoural
immune heterogeneity as a hallmark of tumour evolution and progression
in hepatocellular carcinoma.&nbsp;<em>Nat Commun.,</em>&nbsp;12(1):227.
https://doi.org/10.1038/s41467-020-20171-7. PMID: 33431814.</p>
</li>
<li>
<p>Sharma A, Seow JJW, Dutertre CA, Pai R, Blériot C, Mishra A, Wong RMM,
Singh GSN, Sudhagar S, Khalilnezhad S, Erdal S, Teo HM, Khalilnezhad A,
Chakarov S, Lim TKH, Fui ACY, Chieh AKW, Chung CP, Bonney GK, Goh BK, Chan
JKY,&nbsp;<strong>Chow PKH</strong>, Ginhoux F, DasGupta R. (2020) Onco-fetal
Reprogramming of Endothelial Cells Drives Immunosuppressive Macrophages
in Hepatocellular Carcinoma.&nbsp;<em>Cell</em>, 183(2):377-394.e21. https://doi.org/10.1016/j.cell.2020.08.040.
PMID: 32976798</p>
</li>
<li>
<p>Ding, Z., Ericksen, R, Escande-Beillard, N., Lee, Q.Y, Loh A., Denil,
S., Steckel, M., Andrea Haegebarth, A., Ho, S.W.,&nbsp;<strong>Chow, P.K.</strong>,
Toh, H.C., Reversade, B., Gruenewald, S., Han, W. (2020) Metabolic pathway
analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis.&nbsp;<em>Hepatol.,</em>&nbsp;72(4):725-35,
ISSN 0168-8278, https://doi.org/10.1016/j.jhep.2019.10.026</p>
</li>
<li>
<p>Chong YC, Toh TB, Chan Z, Lin QXX, Thng DKH, Hooi L, Ding Z, Shuen T,
Toh HC, Dan YY, Bonney GK, Zhou L,&nbsp;<strong>Chow P</strong>, Wang Y,
Benoukraf T, Chow EK, Han W. (2020) Targeted Inhibition of Purine Metabolism
Is Effective in Suppressing Hepatocellular Carcinoma Progression.&nbsp;<em>Commun.,</em>&nbsp;4(9):1362-81.
https://doi.org/10.1002/hep4.1559.</p>
</li>
<li>
<p>Jin, Y., Wong, Y.S., Goh, B.K.P., Chan, C.Y., Cheow, P.C.,&nbsp;<strong>Chow, P.K.H.</strong>,
Lim, T.K.H., Goh, G.B.B., Krishnamoorthy, T.L., Kumar, R., Ng, T.P., Chong,
S.S., Tan, H.H., Chung, A.Y.F, Ooi, L.L., Chang, J.P.E., Tan, C.K., and
Lee, C.G.L. (2019) Circulating microRNAs as potential diagnostic and prognostic
biomarkers in hepatocellular carcinoma.&nbsp;<em>Rep.</em>, 9(10464). https://doi.org/10.1038/s41598-019-46872-8</p>
</li>
<li>
<p>Zhao, Y., Shuen, T.W.H., Toh, T.B., Chan, X.Y., Liu, M., Tan, S.Y., Fan,
Y., Yang, H., Lyer, S.G., Bonney, G.K., Loh, E., Chang, K.T.E., Tan, T.C.,
Zhai, W., Chan, J.K.Y., Chow, E.K., Chee, C.E., Lee, G.H., Dan, Y.Y.,&nbsp;<strong>Chow, P.K</strong>.,
Toh, H.C., Lim, S.G., and Chen, Q. (2018). Development of a New Patient-Derived
Xenograft Humanised Mouse Model to Study Human-Specific Tumour Microenvironment
and Immunotherapy.&nbsp;<em>Gut</em>. pii: gutjnl-2017-315201. https://doi.org/10.1136/gutjnl-2017-315201.</p>
</li>
<li>
<p>Lim, C.J., Lee, Y.H., Pan, L., Lai, L., Chua, C., Wasser, M., Lim, T.K.H.,
Yeong, J., Toh, H.C., Lee, S.Y., Chan, C.Y., Goh, B.K., Chung, A., Heikenwalder,
M., Ng, I.O.,&nbsp;<strong>Chow, P.</strong>, Albani, S., and Chew, V.
(2018). Multidimensional Analyses Reveal Distinct Immune Microenvironment
in Hepatitis B Virus-Related Hepatocellular Carcinoma.&nbsp;<em>Gut</em>.
https://doi.org/10.1136/gutjnl-2018-316510.</p>
</li>
<li>
<p><strong>Pierce K.H. Chow</strong>, Mihir Gandhi, Say-Beng Tan, et al.
(2018) SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib
in Asia-Pacific Patients With Hepatocellular Carcinoma.&nbsp;<em>Clin. Oncol.</em>,
JCO2017760892. https://doi.org/10.1200/JCO.2017.76.0892.</p>
</li>
<li>
<p>Chew, V., Lee, Y.H., Pan, L., Nasir, N.J.M., Lim, C.J., Chua, C., Lai,
L., Hazirah, S.N., Lim, T.K.H., Goh, B.K.P., Chung, A., Lo, R.H.G., Ng,
D., Filarca, R.L.F, Albani, S., and&nbsp;<strong>Chow, P.K.H.</strong>&nbsp;(2018).
Immune Activation Underlies a Sustained Clinical Response to Yttrium-90
Radioembolisation in Hepatocellular Carcinoma. Gut. pii: gutjnl-2017-315485.
https://doi.org/10.1136/gutjnl-2017-315485</p>
</li>
<li>
<p>Cheung, T.T., Han, H.S., She, W.H., Chen, K.H.,&nbsp;<strong>Chow, P.K.H.</strong>,
Yoong, B.K., Lee, K.F., Kubo, S., Tang, C.N., and Wakabayashi, G. (2018).
The Asia Pacific Consensus Statement on Laparoscopic Liver Resection for
Hepatocellular Carcinoma: A Report from the 7th Asia-Pacific Primary Liver
Cancer Expert Meeting Held in Hong Kong.&nbsp;<em>Liver Cancer,</em>&nbsp;7:28-39.
https://doi.org/10.1159/000481834.</p>
</li>
<li>
<p>Zhai W, Lim TK, Zhang T, Phang ST, Tiang Z, Guan P, Ng MH, Lim JQ, Yao
F, Li Z, Ng PY, Yan J, Goh BK, Chung AY, Choo SP, Khor CC, Soon WW, Sung
KW, Foo RS,&nbsp;<strong>Chow PK</strong>&nbsp;(2017) The spatial organization
of intra-tumour heterogeneity and evolutionary trajectories of metastases
in hepatocellular carcinoma.&nbsp;<em>Commun.</em>&nbsp;8:4565. https://doi.org/10.1038/ncomms14565</p>
</li>
<li>
<p>Gebski V, Gibbs E, Gandhi M, Chatellier G, Dinut A, Pereira H,&nbsp;<strong>Chow PK</strong>,
Vilgrain V (2017) VESPRO: An Individual Patient Data Prospective Meta-Analysis
of Selective Internal Radiation Therapy Versus Sorafenib for Advanced,
Locally Advanced, or Recurrent Hepatocellular Carcinoma of the SARAH and
SIRveNIB Trials.&nbsp;<em>JMIR Res. Protoc.</em>&nbsp;6(2):17. https://doi.org/1010.2196/resprot.7016.</p>
</li>
<li>
<p><strong>Chow, P.K.</strong>, Gandhi, M., and Gebski, V. (2017). The Sirvenib
and Sarah Trials and the Role of Sir-Spheres(R) Y-90 Resin Microspheres
in the Management of Hepatocellular Carcinoma.&nbsp;_Future Oncol.,_13:2213-16.
https://doi.org/10.2217/fon-2017-0395.</p>
</li>
<li>
<p>Chew V, Lai L, Pan L, Lim CJ, Li J, Ong R, Chua C, Leong JY, Lim KH, Toh
HC, Lee SY, Chan CY, Goh BKP, Chung A,&nbsp;<strong>Chow PKH</strong>,
Albani S. (2017). Delineation of an immunosuppressive gradient in hepatocellular
carcinoma using high-dimensional proteomic and transcriptomic analyses.&nbsp;<em>Natl. Acad. Sci.</em>,
114(29):5900-09. https://doi.org/10.1073/pnas.1706559114.</p>
</li>
<li>
<p>Gandhi M, Choo SP, Thng CH, Tan SB, Low AS, Cheow PC, Goh AS, Tay KH,
Lo RH, Goh BK, Wong JS, Ng DC, Soo KC, Liew WM,&nbsp;<strong>Chow PK</strong>&nbsp;(2016)
Single administration of Selective Internal Radiation Therapy versus continuous
treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB):
study protocol for a phase iii randomized controlled trial.&nbsp;<em>BMC Cancer</em>&nbsp;16(1):856.
https://doi.org/10.1186/s12885-016-2868-y</p>
</li>
<li>
<p><strong>Chow, P. K. H</strong>., Choo, S. P., Ng, D. C. E., Lo, R. H.
G., Wang, M. L. C., Toh, H. C., Tai, D. W. M., Goh, B. K. P., Wong, J.
S., Tay, K. H., Goh, A. S. W., Yan, S. X., Loke, K. S. H., Thang, S. P.,
Gogna, A., Too, C. W., Irani, F. G., Leong, S., Lim, K. H., and Thng, C.
H. 2016. National Cancer Centre Singapore Consensus Guidelines for Hepatocellular
Carcinoma. Liver Cancer 5, 97-106.</p>
</li>
<li>
<p>Garnelo, M., Tan, A., Her, Z., Yeong, J., Lim, C. J., Chen, J., Lim, K.
H., Weber, A.,&nbsp;<strong>Chow, P.</strong>&nbsp;, Chung, A., Ooi, L.
L. P. J., Toh, H. C., Heikenwalder, M., Ng, I. O. L., Nardin, A., Chen,
Q., Abastado, J., Chew, V. 2015. Interaction between tumour-infiltrating
B cells and T cells controls the progression of hepatocellular carcinoma.
Gut doi:10.1136/gutjnl-2015-310814</p>
</li>
<li>
<p>Wang, W., Iyer, N. G., Tay, H. T., Wu, Y., Lim, T. K., Zheng, L., Song,
I. C., Kwoh, C. K., Huynh, H., Tan, P. O. &amp;&nbsp;<strong>Chow, P. K.</strong>&nbsp;2015.
Microarray profiling shows distinct differences between primary tumors
and commonly used preclinical models in hepatocellular carcinoma. BMC Cancer,
15, 828.</p>
</li>
<li>
<p>Teo, J. Y., Allen, J. C., Jr., Ng, D. C., Choo, S. P., Tai, D. W., Chang,
J. P., Cheah, F. K.,&nbsp;<strong>Chow, P. K.</strong>&nbsp;&amp; Goh,
B. K. 2016. A systematic review of contralateral liver lobe hypertrophy
after unilobar selective internal radiation therapy with Y90. HPB (Oxford),
18(1): 7–12.</p>
</li>
<li>
<p>Phillips, R., Gandhi, M., Cheung, Y. B., Findlay, M. P., Win, K. M., Hai,
H. H., Yang, J. M., Lobo, R. R., Soo, K. C. &amp;&nbsp;<strong>Chow, P. K.</strong>&nbsp;2015.
Summary scores captured changes in subjects’ QoL as measured by the multiple
scales of the EORTC QLQ-C30. J Clin Epidemiol, 68, 895-902.</p>
</li>
<li>
<p>Goh, B. K., Chan, C. Y., Wong, J. S., Lee, S. Y., Lee, V. T., Cheow, P.
C.,&nbsp;<strong>Chow, P. K.</strong>, Ooi, L. L. &amp; Chung, A. Y. 2015a.
Factors associated with and outcomes of open conversion after laparoscopic
minor hepatectomy: initial experience at a single institution. Surg Endosc,
29, 2636-42.</p>
</li>
<li>
<p>Ang, S. F., Ng, E. S.-H., Li, H., Ong, Y.-H., Choo, S. P., Ngeow, J.,
Toh, H. C., Lim, K. H., Yap, H. Y., Tan, C. K., Ooi, L. L. P. J., Chung,
A. Y. F.,&nbsp;<strong>Chow, P. K. H.</strong>, Foo, K. F., Tan, M.-H.
&amp; Cheow, P. C. 2015. The Singapore Liver Cancer Recurrence (SLICER)
Score for Relapse Prediction in Patients with Surgically Resected Hepatocellular
Carcinoma. PLoS One, 10, e0118658.</p>
</li>
<li>
<p>Khajornjiraphan N, Thu NA,&nbsp;<strong>Chow PKH</strong>. (2015) Yttrium-90
Microspheres: A Review of Its Emerging Clinical Indications. Liver Cancer
2015; 4: 6-15.</p>
</li>
<li>
<p>Chang PEJ, Purushotham S, Rumpel H, Kee IHC, Ng RTH,&nbsp;<strong>Chow PKH</strong>,
Ramanujan RV and Tan CK. (2014) Novel Dual Magnetic Drug Targeting and
Hyperthermia Therapy in Hepatocellular Carcinoma with Thermosensitive Polymer-Coated
Nanoparticles. J Gastroint Dig Syst 4:198. doi: 10.4172/2161-069X.1000198.</p>
</li>
<li>
<p>Teo, J. Y., Goh, B. K., Cheah, F. K., Allen, J. C., Lo, R. H., Ng, D.
C., Goh, A. S., Khor, A. Y., Sim, H. S., Ng, J. J., and&nbsp;<strong>Chow, P. K.</strong>&nbsp;(2014)
Underlying liver disease influences volumetric changes in the spared hemiliver
after selective internal radiation therapy with 90Y in patients with hepatocellular
carcinoma, Journal of digestive diseases 15, 444-450.</p>
</li>
<li>
<p>Mah, W. C., Thurnherr, T.,&nbsp;<strong>Chow, P. K.</strong>, Chung, A.
Y., Ooi, L. L., Toh, H. C., Teh, B. T., Saunthararajah, Y., and Lee, C.
G. (2014) Methylation profiles reveal distinct subgroup of hepatocellular
carcinoma patients with poor prognosis, PloS one 9, e104158.</p>
</li>
<li>
<p>Lim, K. C., Wang, V. W., Siddiqui, F. J., Shi, L., Chan, E. S., Oh, H.
C., Tan, S. B., and&nbsp;<strong>Chow, P. K.</strong>&nbsp;(2014) Cost-effectiveness
analysis of liver resection versus transplantation for early hepatocellular
carcinoma within the Milan criteria, Hepatology, 61(1):227-37. doi: 10.1002/hep.27135.
Epub 2014 May 29.</p>
</li>
<li>
<p>Khor, A.-K., Toh, Y., Allen, J., Ng, D.-E., Kao, Y.-H., Zhu, G., Choo,
S.-P., Lo, R.-G., Tay, K.-H., Teo, J.-Y., Goh, B.-P., Burgmans, M., Irani,
F., Goh, A.-W., and&nbsp;<strong>Chow, P.-H.</strong>. (2014) Survival
and pattern of tumor progression with yttrium-90 microsphere radioembolization
in predominantly hepatitis B Asian patients with hepatocellular carcinoma,
Hepatology international 8, 395-404.</p>
</li>
<li>
<p>Kao, Y. H., Tan, A. E., Lo, R. H., Tay, K. H., Tan, B. S.,&nbsp;<strong>Chow, P. K.</strong>,
Ng, D. C., and Goh, A. S. (2014) Non-Target Activity Detection by Post-Radioembolization
Yttrium-90 PET/CT: Image Assessment Technique and Case Examples, Frontiers
in oncology 4, 11.</p>
</li>
<li>
<p>Kao, Y. H., Magsombol, B. M., Toh, Y., Tay, K. H.,&nbsp;<strong>Chow, P.</strong>,
Goh, A. S., and Ng, D. C. (2014) Personalized predictive lung dosimetry
by technetium-99m macroaggregated albumin SPECT/CT for yttrium-90 radioembolization,
EJNMMI Res 4, 33.</p>
</li>
<li>
<p>Goh, B. K.,&nbsp;<strong>Chow, P. K.</strong>, Teo, J. Y., Wong, J. S.,
Chan, C. Y., Cheow, P. C., Chung, A. Y., and Ooi, L. L. (2014) Number of
nodules, Child-Pugh status, margin positivity, and microvascular invasion,
but not tumor size, are prognostic factors of survival after liver resection
for multifocal hepatocellular carcinoma, Journal of gastrointestinal surgery
: official journal of the Society for Surgery of the Alimentary Tract 18,
1477-1485.</p>
</li>
<li>
<p><strong>Chow, P. K.</strong>, Poon, D. Y., Khin, M. W., Singh, H., Han,
H. S., Goh, A. S., Choo, S. P., Lai, H. K., Lo, R. H., Tay, K. H., Lim,
T. G., Gandhi, M., Tan, S. B., and Soo, K. C. (2014) Multicenter phase
II study of sequential radioembolization-sorafenib therapy for inoperable
hepatocellular carcinoma, PloS one 9, e90909.</p>
</li>
<li>
<p>Zech, C. J., Bartolozzi, C., Bioulac-Sage, P.,&nbsp;<strong>Chow, P. K.</strong>,
Forner, A., Grazioli, L., Huppertz, A., Laumonier, H., Min Lee, J., Murakami,
T., Ricke, J., and Sirlin, C. B. (2013) Consensus report of the Fifth International
Forum for Liver MRI, AJR. American journal of roentgenology 201, 97-107.</p>
</li>
<li>
<p>Xu, Q., Leong, J., Chua, Q. Y., Chi, Y. T.,&nbsp;<strong>Chow, P. K.</strong>,
Pack, D. W., and Wang, C. H. (2013) Combined modality doxorubicin-based
chemotherapy and chitosan-mediated p53 gene therapy using double-walled
microspheres for treatment of human hepatocellular carcinoma, Biomaterials
34, 5149-5162.</p>
</li>
<li>
<p>Wang, Y., Ren, J., Gao, Y., Ma, J. Z., Toh, H. C.,&nbsp;<strong>Chow, P.</strong>,
Chung, A. Y., Ooi, L. L., and Lee, C. G. (2013) MicroRNA-224 targets SMAD
family member 4 to promote cell proliferation and negatively influence
patient survival, PloS one 8, e68744.</p>
</li>
<li>
<p>Toh, S. T., Jin, Y., Liu, L., Wang, J., Babrzadeh, F., Gharizadeh, B.,
Ronaghi, M., Toh, H. C.,&nbsp;<strong>Chow, P. K.</strong>, Chung, A. Y.,
Ooi, L. L., and Lee, C. G. (2013) Deep sequencing of the hepatitis B virus
in hepatocellular carcinoma patients reveals enriched integration events,
structural alterations and sequence variations, Carcinogenesis 34, 787-798.</p>
</li>
<li>
<p>Lau, W. Y., Sangro, B., Chen, P. J., Cheng, S. Q.,&nbsp;<strong>Chow, P.</strong>,
Lee, R. C., Leung, T., Han, K. H., and Poon, R. T. (2013) Treatment for
hepatocellular carcinoma with portal vein tumor thrombosis: the emerging
role for radioembolization using yttrium-90, Oncology 84, 311-318.</p>
</li>
<li>
<p>Kong, N. H. Y., and&nbsp;<strong>Chow, P. K. H</strong>. (2013) Conducting
randomised controlled trials across countries with disparate levels of
socio-economic development: The experience of the Asia-Pacific Hepatocellular
Carcinoma Trials Group, Contemporary Clinical Trials 36, 682-686.</p>
</li>
<li>
<p>Kong, N. H., and&nbsp;<strong>Chow, P.</strong>&nbsp;(2013) Conflict of
Interest in Research – The Clinician Scientist’s Perspective, Annals of
the Academy of Medicine, Singapore 42, 623-628.</p>
</li>
<li>
<p>Kao, Y.-H., Steinberg, J., Tay, Y.-S., Lim, G., Yan, J., Townsend, D.,
Takano, A., Burgmans, M., Irani, F., Teo, T., Yeow, T.-N., Gogna, A., Lo,
R., Tay, K.-H., Tan, B.-S.,&nbsp;<strong>Chow, P.</strong>, Satchithanantham,
S., Tan, A., Ng, D., and Goh, A. (2013) Post-radioembolization yttrium-90
PET/CT – part 1: diagnostic reporting, EJNMMI Res 3, 56.</p>
</li>
<li>
<p>Kao, Y.-H., Steinberg, J., Tay, Y.-S., Lim, G., Yan, J., Townsend, D.,
Budgeon, C., Boucek, J., Francis, R., Cheo, T., Burgmans, M., Irani, F.,
Lo, R., Tay, K.-H., Tan, B.-S.,&nbsp;<strong>Chow, P.</strong>, Satchithanantham,
S., Tan, A., Ng, D., and Goh, A. (2013) Post-radioembolization yttrium-90
PET/CT – part 2: dose-response and tumor predictive dosimetry for resin
microspheres, EJNMMI Research 3, 57.</p>
</li>
<li>
<p>Chung, A. Y., Ooi, L. L., Machin, D., Tan, S. B., Goh, B. K., Wong, J.
S., Chen, Y. M., Li, P. C., Gandhi, M., Thng, C. H., Yu, S. W., Tan, B.
S., Lo, R. H., Htoo, A. M., Tay, K. H., Sundram, F. X., Goh, A. S., Chew,
S. P., Liau, K. H.,&nbsp;<strong>Chow, P. K.</strong>, Tan, Y. M., Cheow,
P. C., Ho, C. K., and Soo, K. C. (2013) Adjuvant hepatic intra-arterial
iodine-131-lipiodol following curative resection of hepatocellular carcinoma:
a prospective randomized trial, World journal of surgery 37, 1356-1361.</p>
</li>
<li>
<p>Chan, C., Wang, Y.,&nbsp;<strong>Chow, P. K.</strong>, Chung, A. Y., Ooi,
L. L., and Lee, C. G. (2013) Altered binding site selection of p53 transcription
cassettes by hepatitis B virus X protein, Molecular and cellular biology
33, 485-497.</p>
</li>
<li>
<p>Wang, Y., Toh, H. C.,&nbsp;<strong>Chow, P.</strong>, Chung, A. Y., Meyers,
D. J., Cole, P. A., Ooi, L. L., and Lee, C. G. (2012) MicroRNA-224 is up-regulated
in hepatocellular carcinoma through epigenetic mechanisms, FASEB journal
: official publication of the Federation of American Societies for Experimental
Biology 26, 3032-3041.</p>
</li>
<li>
<p>Lim, K. C.,&nbsp;<strong>Chow, P. K.</strong>, Allen, J. C., Siddiqui,
F. J., Chan, E. S., and Tan, S. B. (2012) Systematic review of outcomes
of liver resection for early hepatocellular carcinoma within the Milan
criteria, The British journal of surgery 99, 1622-1629.</p>
</li>
<li>
<p>Kao, Y. H., Hock Tan, A. E., Burgmans, M. C., Irani, F. G., Khoo, L. S.,
Gong Lo, R. H., Tay, K. H., Tan, B. S., Hoe&nbsp;<strong>Chow, P. K.</strong>,
Eng Ng, D. C., and Whatt Goh, A. S. (2012) Image-guided personalized predictive
dosimetry by artery-specific SPECT/CT partition modeling for safe and effective
90Y radioembolization, Journal of nuclear medicine : official publication,
Society of Nuclear Medicine 53, 559-566.</p>
</li>
<li>
<p>Huynh, H.,&nbsp;<strong>Chow, P. K.</strong>, Tai, W. M., Choo, S. P.,
Chung, A. Y., Ong, H. S., Soo, K. C., Ong, R., Linnartz, R., and Shi, M.
M. (2012) Dovitinib demonstrates antitumor and antimetastatic activities
in xenograft models of hepatocellular carcinoma, Journal of hepatology
56, 595-601.</p>
</li>
<li>
<p><strong>Chow, P. K.</strong>&nbsp;(2012) Resection for hepatocellular
carcinoma: is it justifiable to restrict this to the American Association
for the Study of the Liver/Barcelona Clinic for Liver Cancer criteria?,
Journal of gastroenterology and hepatology 27, 452-457.</p>
</li>
<li>
<p>Burgmans, M. C., Too, C. W., Kao, Y. H., Goh, A. S.,&nbsp;<strong>Chow, P. K.</strong>,
Tan, B. S., Tay, K. H., and Lo, R. H. (2012) Computed tomography hepatic
arteriography has a hepatic falciform artery detection rate that is much
higher than that of digital subtraction angiography and 99mTc-MAA SPECT/CT:
implications for planning 90Y radioembolization?, European journal of radiology
81, 3979-3984.</p>
</li>
<li>
<p>Burgmans, M. C., Kao, Y. H., Irani, F. G., Dames, E. L., Teo, T. K., Goh,
A. S.,&nbsp;<strong>Chow, P. K.</strong>, Tay, K. H., and Lo, R. H. (2012)
Radioembolization with infusion of yttrium-90 microspheres into a right
inferior phrenic artery with hepatic tumor supply is feasible and safe,
Journal of vascular and interventional radiology : JVIR 23, 1294-1301.</p>
</li>
<li>
<p>Burgmans, M. C., Irani, F. G., Chan, W. Y., Teo, T. K., Kao, Y. H., Goh,
A. S.,&nbsp;<strong>Chow, P. K.</strong>, and Lo, R. H. (2012) Radioembolization
after portal vein embolization in a patient with multifocal hepatocellular
carcinoma, Cardiovascular and interventional radiology 35, 1519-1523.</p>
</li>
<li>
<p>Thian, Y. L., Low, A. S.,&nbsp;<strong>Chow, P. K.</strong>, Ooi, L. L.,
Chung, A. Y., Low, S. C., Xie, W., and Thng, C. H. (2011) Atypical enhancement
pattern of hepatocellular carcinoma with portal vein thrombosis on multiphasic
CT, Annals of the Academy of Medicine, Singapore 40, 454-459.</p>
</li>
<li>
<p>Tan, C. H., Thng, C. H., Low, A. S., Tan, V. K., Hartono, S., Koh, T.
S., Goh, B. K., Cheow, P. C., Tan, Y. M., Chung, A. Y., Ooi, L. L., Earnest,
A., and&nbsp;<strong>Chow, P. K.</strong>&nbsp;(2011) Wash-out of hepatocellular
carcinoma: quantitative region of interest analysis on CT, Annals of the
Academy of Medicine, Singapore 40, 269-275.</p>
</li>
<li>
<p>Lim, L.,&nbsp;<strong>Chow, P.</strong>, Wong, C. Y., Chung, A., Chan,
Y. H., Wong, W. K., and Soo, K. C. (2011) Doctor-patient communication,
knowledge, and question prompt lists in reducing preoperative anxiety:
a randomized control study, Asian journal of surgery / Asian Surgical Association
34, 175-180.</p>
</li>
<li>
<p>Lim, K. C.,&nbsp;<strong>Chow, P. K.</strong>, Allen, J. C., Chia, G.
S., Lim, M., Cheow, P. C., Chung, A. Y., Ooi, L. L., and Tan, S. B. (2011)
Microvascular invasion is a better predictor of tumor recurrence and overall
survival following surgical resection for hepatocellular carcinoma compared
to the Milan criteria, Annals of surgery 254, 108-113.</p>
</li>
<li>
<p>Kao, Y. H., Tan, A. E., Khoo, L. S., Lo, R. H.,&nbsp;<strong>Chow, P. K.</strong>,
and Goh, A. S. (2011) Hepatic falciform ligament Tc-99m-macroaggregated
albumin activity on SPECT/CT prior to Yttrium-90 microsphere radioembolization:
prophylactic measures to prevent non-target microsphere localization via
patent hepatic falciform arteries, Annals of nuclear medicine 25, 365-369.</p>
</li>
<li>
<p>Huynh, H., Choo, S. P., Toh, H. C., Tai, W. M., Chung, A. Y.,&nbsp;<strong>Chow, P. K.</strong>,
Ong, R., and Soo, K. C. (2011) Comparing the efficacy of sunitinib with
sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic
explanation, Current cancer drug targets 11, 944-953.</p>
</li>
<li>
<p>Han, K. H., Kudo, M., Ye, S. L., Choi, J. Y., Poon, R. T., Seong, J.,
Park, J. W., Ichida, T., Chung, J. W.,&nbsp;<strong>Chow, P.</strong>,
and Cheng, A. L. (2011) Asian consensus workshop report: expert consensus
guideline for the management of intermediate and advanced hepatocellular
carcinoma in Asia, Oncology 81 Suppl 1, 158-164.</p>
</li>
<li>
<p><strong>Chow, P. K.</strong>, Machin, D., Chen, Y., Zhang, X., Win, K.
M., Hoang, H. H., Nguyen, B. D., Jin, M. Y., Lobo, R., Findlay, M., Lim,
C. H., Tan, S. B., Gandhi, M., and Soo, K. C. (2011) Randomised double-blind
trial of megestrol acetate vs placebo in treatment-naive advanced hepatocellular
carcinoma, British journal of cancer 105, 945-952.</p>
</li>
<li>
<p>Chanyaputhipong, J., Low, S. C., and&nbsp;<strong>Chow, P. K.</strong>&nbsp;(2011)
Gadoxetate Acid-Enhanced MR Imaging for HCC: A Review for Clinicians, International
journal of hepatology 2011, 489342.</p>
</li>
<li>
<p>Wang, Y., Lu, Y., Toh, S. T., Sung, W. K., Tan, P.,&nbsp;<strong>Chow, P.</strong>,
Chung, A. Y., Jooi, L. L., and Lee, C. G. (2010) Lethal-7 is down-regulated
by the hepatitis B virus x protein and targets signal transducer and activator
of transcription 3, Journal of hepatology 53, 57-66.</p>
</li>
<li>
<p>Omata, M., Lesmana, L. A., Tateishi, R., Chen, P. J., Lin, S. M., Yoshida,
H., Kudo, M., Lee, J. M., Choi, B. I., Poon, R. T., Shiina, S., Cheng,
A. L., Jia, J. D., Obi, S., Han, K. H., Jafri, W.,&nbsp;<strong>Chow, P.</strong>,
Lim, S. G., Chawla, Y. K., Budihusodo, U., Gani, R. A., Lesmana, C. R.,
Putranto, T. A., Liaw, Y. F., and Sarin, S. K. (2010) Asian Pacific Association
for the Study of the Liver consensus recommendations on hepatocellular
carcinoma, Hepatology international 4, 439-474.</p>
</li>
<li>
<p>Jia, J., Wang, J., Teh, M., Sun, W., Zhang, J., Kee, I.,&nbsp;<strong>Chow, P. K.</strong>,
Liang, R. C., Chung, M. C., and Ge, R. (2010) Identification of proteins
differentially expressed between capillary endothelial cells of hepatocellular
carcinoma and normal liver in an orthotopic rat tumor model using 2-D DIGE,
Proteomics 10, 224-234.</p>
</li>
<li>
<p>Huynh, H., Ngo, V. C., Koong, H. N., Poon, D., Choo, S. P., Toh, H. C.,
Thng, C. H.,&nbsp;<strong>Chow, P.</strong>, Ong, H. S., Chung, A., Goh,
B. C., Smith, P. D., and Soo, K. C. (2010) AZD6244 enhances the anti-tumor
activity of sorafenib in ectopic and orthotopic models of human hepatocellular
carcinoma (HCC), Journal of hepatology 52, 79-87.</p>
</li>
<li>
<p>Taneja, M., Lo, R., Sebastian, M., and&nbsp;<strong>Chow, P.</strong>&nbsp;(2009)
Intra-hepatic arterial pseudoaneurysm causing life-threatening upper gastrointestinal
bleed after removal of biliary drainage catheter, Biomedical imaging and
intervention journal 5, e20.</p>
</li>
<li>
<p>Samuel, M.,&nbsp;<strong>Chow, P. K.</strong>, Chan Shih-Yen, E., Machin,
D., and Soo, K. C. (2009) Neoadjuvant and adjuvant therapy for surgical
resection of hepatocellular carcinoma, Cochrane Database Syst Rev, CD001199.</p>
</li>
<li>
<p>Purushotham, S., Chang, P. E., Rumpel, H., Kee, I. H., Ng, R. T.,&nbsp;<strong>Chow, P. K.</strong>,
Tan, C. K., and Ramanujan, R. V. (2009) Thermoresponsive core-shell magnetic
nanoparticles for combined modalities of cancer therapy, Nanotechnology
20, 305101.</p>
</li>
<li>
<p>Poon, D., Anderson, B. O., Chen, L. T., Tanaka, K., Lau, W. Y., Van Cutsem,
E., Singh, H., Chow, W. C., Ooi, L. L.,&nbsp;<strong>Chow, P.</strong>,
Khin, M. W., and Koo, W. H. (2009) Management of hepatocellular carcinoma
in Asia: consensus statement from the Asian Oncology Summit 2009, The lancet
oncology 10, 1111-1118.</p>
</li>
<li>
<p>Ong, L. C., Song, I. C., Jin, Y., Kee, I. H., Siew, E., Yu, S., Thng,
C. H., Huynh, H., and&nbsp;<strong>Chow, P. K.</strong>&nbsp;(2009) Effective
inhibition of xenografts of hepatocellular carcinoma (HepG2) by rapamycin
and bevacizumab in an intrahepatic model, Molecular imaging and biology
: MIB : the official publication of the Academy of Molecular Imaging 11,
334-342.</p>
</li>
<li>
<p>Loa, J.,&nbsp;<strong>Chow, P.</strong>, and Zhang, K. (2009) Studies
of structure-activity relationship on plant polyphenol-induced suppression
of human liver cancer cells, Cancer chemotherapy and pharmacology 63, 1007-1016.</p>
</li>
<li>
<p>Leong, Q. M., Lai, H. K., Lo, R. G., Teo, T. K., Goh, A., and&nbsp;<strong>Chow, P. K.</strong>&nbsp;(2009)
Radiation dermatitis following radioembolization for hepatocellular carcinoma:
a case for prophylactic embolization of a patent falciform artery, Journal
of vascular and interventional radiology : JVIR 20, 833-8363</p>
</li>
<li>
<p>Huynh, H., Ngo, V. C., Koong, H. N., Poon, D., Choo, S. P., Thng, C. H.,&nbsp;<strong>Chow, P.</strong>,
Ong, H. S., Chung, A., and Soo, K. C. (2009) Sorafenib and rapamycin induce
growth suppression in mouse models of hepatocellular carcinoma, Journal
of cellular and molecular medicine 13, 2673-2683.</p>
</li>
<li>
<p>Huynh, H., Ngo, V. C., Choo, S. P., Poon, D., Koong, H. N., Thng, C. H.,
Toh, H. C., Zheng, L., Ong, L. C., Jin, Y., Song, I. C., Chang, A. P.,
Ong, H. S., Chung, A. Y.,&nbsp;<strong>Chow, P. K.</strong>, and Soo, K.
C. (2009) Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces
apoptosis in xenograft models of human hepatocellular carcinoma, Current
cancer drug targets 9, 738-747.</p>
</li>
<li>
<p>Huynh, H.,&nbsp;<strong>Chow, P. K.</strong>, Soo, K. C., Toh, H. C.,
Choo, S. P., Foo, K. F., Poon, D., Ngo, V. C., and Tran, E. (2009) RAD001
(everolimus) inhibits tumour growth in xenograft models of human hepatocellular
carcinoma, Journal of cellular and molecular medicine 13, 1371-1380.</p>
</li>
<li>
<p>Huynh, H., Ngo, V. C., Fargnoli, J., Ayers, M., Soo, K. C., Koong, H.
N., Thng, C. H., Ong, H. S., Chung, A.,&nbsp;<strong>Chow, P.</strong>,
Pollock, P., Byron, S., and Tran, E. (2008) Brivanib alaninate, a dual
inhibitor of vascular endothelial growth factor receptor and fibroblast
growth factor receptor tyrosine kinases, induces growth inhibition in mouse
models of human hepatocellular carcinoma, Clinical cancer research : an
official journal of the American Association for Cancer Research 14, 6146-6153.</p>
</li>
<li>
<p>Huynh, H.,&nbsp;<strong>Chow, P. K.</strong>, Palanisamy, N., Salto-Tellez,
M., Goh, B. C., Lee, C. K., Somani, A., Lee, H. S., Kalpana, R., Yu, K.,
Tan, P. H., Wu, J., Soong, R., Lee, M. H., Hor, H., Soo, K. C., Toh, H.
C., and Tan, P. (2008) Bevacizumab and rapamycin induce growth suppression
in mouse models of hepatocellular carcinoma, Journal of hepatology 49,
52-60.</p>
</li>
<li>
<p>Ang, M. K., Poon, D., Foo, K. F., Chung, Y. F.,&nbsp;<strong>Chow, P.</strong>,
Wan, W. K., Thng, C. H., and Ooi, L. (2008) A new chemoimmunotherapy regimen
(OXAFI) for advanced hepatocellular carcinoma, Hematology/oncology and
stem cell therapy 1, 159-165</p>
</li>
<li>
<p>Thia, T. J., Lui, H. F., Ooi, L. L., Chung, Y. F.,&nbsp;<strong>Chow, P. K.</strong>,
Cheow, P. C., Tan, Y. M., and Chow, W. C. (2007) A study into the risk
of exacerbation of chronic hepatitis B after liver resection for hepatocellular
carcinoma, Journal of gastrointestinal surgery : official journal of the
Society for Surgery of the Alimentary Tract 11, 612-618.</p>
</li>
<li>
<p>Ong, J. C.,&nbsp;<strong>Chow, P. K.</strong>, Chan, W. H., Chung, A.
Y., Thng, C. H., and Wong, W. K. (2007) Hepatocellular carcinoma masquerading
as a bleeding gastric ulcer: a case report and a review of the surgical
management, World journal of gastroenterology : WJG 13, 4523-4525.</p>
</li>
<li>
<p>Huynh, H., Soo, K. C.,&nbsp;<strong>Chow, P. K.</strong>, and Tran, E.
(2007) Targeted inhibition of the extracellular signal-regulated kinase
kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular
carcinoma, Molecular cancer therapeutics 6, 138-146.</p>
</li>
<li>
<p>Huynh, H.,&nbsp;<strong>Chow, P. K.</strong>, and Soo, K. C. (2007) AZD6244
and doxorubicin induce growth suppression and apoptosis in mouse models
of hepatocellular carcinoma, Molecular cancer therapeutics 6, 2468-2476.</p>
</li>
<li>
<p>Goh, A. S., Chung, A. Y., Lo, R. H., Lau, T. N., Yu, S. W., Chng, M.,
Satchithanantham, S., Loong, S. L., Ng, D. C., Lim, B. C., Connor, S.,
and&nbsp;<strong>Chow, P. K.</strong>&nbsp;(2007) A novel approach to brachytherapy
in hepatocellular carcinoma using a phosphorous32 (32P) brachytherapy delivery
device–a first-in-man study, International journal of radiation oncology,
biology, physics 67, 786-792.</p>
</li>
<li>
<p>AS, M. M., Tan, Y. M., Thng, C. H., Cheow, P. C., Chung, Y. F.,&nbsp;<strong>Chow, P. K.</strong>,
and Ooi, L. L. (2007) Pedunculated HCC or adrenal metastasis: a diagnostic
conundrum, Singapore medical journal 48, e50-52.</p>
</li>
<li>
<p>Tan, F. L., Tan, Y. M., Chung, A. Y., Cheow, P. C.,&nbsp;<strong>Chow, P. K.</strong>,
and Ooi, L. L. (2006) Factors affecting early mortality in spontaneous
rupture of hepatocellular carcinoma, ANZ journal of surgery 76, 448-452.</p>
</li>
<li>
<p>Low, S. C., Lo, R. H., Lau, T. N., Ooi, L. L., Ho, C. K., Tan, B. S.,
Chung, A. Y., Koo, W. H., and&nbsp;<strong>Chow, P. K.</strong>&nbsp;(2006)
Image-guided radiofrequency ablation of liver malignancies: experience
at Singapore General Hospital, Annals of the Academy of Medicine, Singapore
35, 851-857.</p>
</li>
<li>
<p>Huynh, H., Soo, K. C.,&nbsp;<strong>Chow, P. K.</strong>, Panasci, L.,
and Tran, E. (2006) Xenografts of human hepatocellular carcinoma: a useful
model for testing drugs, Clinical cancer research : an official journal
of the American Association for Cancer Research 12, 4306-4314.</p>
</li>
<li>
<p>Zhang, K., Loong, S. L., Connor, S., Yu, S. W., Tan, S. Y., Ng, R. T.,
Lee, K. M., Canham, L., and&nbsp;<strong>Chow, P. K.</strong>&nbsp;(2005)
Complete tumor response following intratumoral 32P BioSilicon on human
hepatocellular and pancreatic carcinoma xenografts in nude mice, Clinical
cancer research : an official journal of the American Association for Cancer
Research 11, 7532-7537.</p>
</li>
<li>
<p>Yang, E. B., Cao, J., Su, J. J., and&nbsp;<strong>Chow, P.</strong>&nbsp;(2005)
The tree shrews: useful animal models for the viral hepatitis and hepatocellular
carcinoma, Hepato-gastroenterology 52, 613-616.</p>
</li>
<li>
<p>Nowak, A. K., Stockler, M. R.,&nbsp;<strong>Chow, P. K.</strong>, and
Findlay, M. (2005) Use of tamoxifen in advanced-stage hepatocellular carcinoma.
A systematic review, Cancer 103, 1408-1414.</p>
</li>
<li>
<p>Hung, H.,&nbsp;<strong>Pierce, C. K.</strong>, Chee, S. K., Lawrence,
P., and Hung, N. T. (2005) SarCNU-induced G2/M arrest in hepatoma cells
is mediated by a p53-independent phosphorylation of cdc-2 at Tyr15, Journal
of cellular physiology 204, 785-791.</p>
</li>
<li>
<p>Chung, Y. F., Thng, C. H., Lui, H. F., Mancer, K.,&nbsp;<strong>Chow, P. K.</strong>,
Tan, Y. M., Cheow, P. C., and Ooi, L. L. (2005) Clinical mimicry of hepatocellular
carcinoma: imaging-pathological correlation, Singapore medical journal
46, 31-36; quiz 37.</p>
</li>
<li>
<p><strong>Chow, P. K.</strong>&nbsp;(2005) Tamoxifen does not improve overall
survival in people with advanced-stage hepatocellular carcinoma, Cancer
Treat Rev 31, 491-495.</p>
</li>
<li>
<p>Zhang, K., and&nbsp;<strong>Chow, P. K.</strong>&nbsp;(2004) The effect
of megestrol acetate on growth of HepG2 cells in vitro and in vivo, Clinical
cancer research : an official journal of the American Association for Cancer
Research 10, 5226-5232.</p>
</li>
<li>
<p>Nowak, A. K.,&nbsp;<strong>Chow, P. K.</strong>, and Findlay, M. (2004)
Systemic therapy for advanced hepatocellular carcinoma: a review, Eur J
Cancer 40, 1474-1484.</p>
</li>
<li>
<p>Huynh, H., Do, P. T., Nguyen, T. H.,&nbsp;<strong>Chow, P.</strong>, Tan,
P. H., Quach, T. H., Van, T., Soo, K. C., and Tran, E. (2004) Extracellular
signal-regulated kinase induces cyclin D1 and Cdk-2 expression and phosphorylation
of retinoblastoma in hepatocellular carcinoma, Int J Oncol 25, 1839-1847</p>
</li>
<li>
<p>Yang, E. B., Qin, L. L., Zhao, Y. N., Zhang, K., and&nbsp;<strong>Chow, P.</strong>&nbsp;(2003)
Genetic changes and expression of the mannose 6-phosphate/insulin-like
growth factor II receptor gene in human hepatitis B virus-associated hepatocellular
carcinoma, International journal of molecular medicine 11, 773-778.</p>
</li>
<li>
<p>Wong, C. H.,&nbsp;<strong>Chow, P. K.</strong>, Koong, H. N., Chung, A.,
and Thng, C. H. (2003) Superior diaphragmatic adenopathy from primary hepatocellular
carcinoma, Journal of gastroenterology and hepatology 18, 352-354.</p>
</li>
<li>
<p>Tseng, G. Y., Thng, C. H., Wong, E. H., Tan, A. G., Suman, P., Quek, S.
T., Ho, J. T., Khoo, J. K., Ooi, L. L.,&nbsp;<strong>Chow, P. K.</strong>,
Chung, Y. F., and Teh, C. S. (2003) Breath-hold fast recovery fast spin
echo versus conventional non-breath-hold fast spin echo T2-weighted MR
imaging of focal liver lesions, Annals of the Academy of Medicine, Singapore
32, 450-454.</p>
</li>
<li>
<p>Huynh, H., Nguyen, T. T.,&nbsp;<strong>Chow, K. H.</strong>, Tan, P. H.,
Soo, K. C., and Tran, E. (2003) Over-expression of the mitogen-activated
protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its
role in tumor progression and apoptosis, BMC Gastroenterol 3, 19.</p>
</li>
<li>
<p>Huynh, H.,&nbsp;<strong>Chow, P. K.</strong>, Ooi, L. L., and Soo, K.
C. (2002) A possible role for insulin-like growth factor-binding protein-3
autocrine/paracrine loops in controlling hepatocellular carcinoma cell
proliferation, Cell growth &amp; differentiation : the molecular biology
journal of the American Association for Cancer Research 13, 115-122.</p>
</li>
<li>
<p>Chung, A. Y., Ng, S. B., Thng, C. H.,&nbsp;<strong>Chow, P. K.</strong>,
and Ooi, L. P. (2002) Hepatic angiomyolipoma mimicking hepatocellular carcinoma,
Asian journal of surgery / Asian Surgical Association 25, 251-254.</p>
</li>
<li>
<p><strong>Chow, P. K.</strong>, Tai, B. C., Tan, C. K., Machin, D., Win,
K. M., Johnson, P. J., and Soo, K. C. (2002) High-dose tamoxifen in the
treatment of inoperable hepatocellular carcinoma: A multicenter randomized
controlled trial, Hepatology 36, 1221-1226.</p>
</li>
<li>
<p><strong>Chow, P. K.</strong>, Hung, H., and Soo, K. C. (2001) Re: Liu
et al.–Estrogen receptor status in inoperable hepatocellular carcinoma,
The American journal of gastroenterology 96, 1297-1298.</p>
</li>
<li>
<p>Tan, C. K.,&nbsp;<strong>Chow, P. K.</strong>, Findlay, M., Wong, C.,
and Machin, D. (2000) Use of tamoxifen in hepatocellular carcinoma: a review
and paradigm shift, Journal of gastroenterology and hepatology 15, 725-729.</p>
</li>
<li>
<p>Chan, E. S.,&nbsp;<strong>Chow, P. K.</strong>, Tai, B., Machin, D., and
Soo, K. (2000) Neoadjuvant and adjuvant therapy for operable hepatocellular
carcinoma, Cochrane Database Syst Rev, CD001199.</p>
</li>
<li>
<p>Sun, L.,&nbsp;<strong>Chow, P. K.</strong>, Fook-Chong, S. M., Chew, M.,
Aw, S. E., and Soo, K. C. (1999) Liver regeneration after partial hepatectomy
is non-uniform: flow cytometric bromodeoxyuridine incorporation and cell
cycle studies in a porcine model, Research in experimental medicine. Zeitschrift
fur die gesamte experimentelle Medizin einschliesslich experimenteller
Chirurgie 198, 229-236.</p>
</li>
<li>
<p><strong>Chow, P.</strong>, Kiat, T. C., Choo, T. B., and Machin, D. (1998)
Tamoxifen in hepatocellular carcinoma, Lancet 352, 819-820.</p>
</li>
</ol>
<p></p>